Science & Technology
Novel and functionally selective 5-HT2C receptor agonist for treating Alcohol Use Disorder
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1U43AA032128-01
Award Ceiling
$1.0M
Award Floor
$1.0M
Close Date
Jul 31, 2027
503 days leftTotal Funding
$1.0M
Expected Awards
1
Posted Date
Aug 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1U43AA032128-01
Description
SBIR Phase Phase I award: "Novel and functionally selective 5-HT2C receptor agonist for treating Alcohol Use Disorder" awarded to Kuleon LLC in SEATTLE, Washington. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,001,425. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.